Results 231 to 240 of about 1,501,016 (387)

Psychotherapy and Placebo [PDF]

British Journal of Psychiatry, 1986
openaire   +8 more sources

Efficacy and Safety of Histamine H3 Receptor Antagonist/Inverse Agonist Including Betahistine for Schizophrenia: A Systematic Review and Meta-Analysis. [PDF]

Neuropsychopharmacol Rep
Nishii Y, Sakuma K, Hamanaka S, Iwata N, Kishi T.   +4 more
europepmc   +1 more source

Hyperbaric oxygen and multiple sclerosis: final results of a placebo-controlled, double-blind trial. [PDF]

, 1987
M P Barnes, D. Bates, N.E.F. Cartlidge, J. M. French, D.A. Shaw   +4 more
openalex   +1 more source

Importance of Considering the Gout Flare: Let's Learn to Walk and Chew Gum at the Same Time in Gout Clinical Trial Design

Arthritis &Rheumatology, EarlyView.
Lisa K. Stamp, Martin A. Kennedy, Nicola Dalbeth   +2 more
wiley   +1 more source

Pharmacology and safety of TAS5315, a Bruton tyrosine kinase inhibitor, in healthy volunteers: First‐in‐human, randomized, ascending‐dose studies

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim TAS5315 is a Bruton tyrosine kinase (Btk) inhibitor in development for autoimmune and allergic diseases, including rheumatoid arthritis (RA) and chronic spontaneous urticaria (CSU). Two clinical studies evaluated the pharmacology and safety of single and multiple oral doses of TAS5315.
Yuji Kumagai, Tomoe Fujita, Mika Maeda, Akiko Yamamoto, Hideki Amano   +4 more
wiley   +1 more source

Efficacy and safety of inhaled ambroxol hydrochloride solution in patients with lower respiratory tract infectious diseases: a randomized, double-blind, placebo-controlled, multicentre clinical trial. [PDF]

BMC Infect Dis
Wu D, Fu X, Jin F, Li H, Qin Z, Wang H, Yue H, Zhang J, Cao Z.   +8 more
europepmc   +1 more source

Placebo-Induced Changes in fMRI in the Anticipation and Experience of Pain

Science, 2004
T. Wager, J. Rilling, Edward E. Smith, A. Sokolik, K. Casey, R. Davidson, S. Kosslyn, R. Rose, J. Cohen   +8 more
semanticscholar   +1 more source

Management of hypotension in dihydropyridine calcium channel blocker overdose: The role of high‐dose insulin therapy

British Journal of Clinical Pharmacology, EarlyView.
Aims Amlodipine poisoning is a leading cause of cardiovascular medication‐related deaths, commonly managed with high‐dose insulin (HDI) therapy. However, HDI is a vasodilator that is counterproductive in managing vasoplegia. We aim to study HDI therapy in patients with hypotension following dihydropyridine calcium channel antagonist (CCA) overdose ...
Betty S. H. Chan, Katherine Z. Isoardi, Darren M. Roberts, Ong Sook Har   +3 more
wiley   +1 more source

A network meta-analysis of efficacy and safety of adjuvant targeted therapy or immunotherapy in non-small cell lung cancer. [PDF]

Sci Rep
Sa-Nguansai S, Rattanasiri S, Pornsuriyasak P, Numthavaj P, McKay GJ, Attia J, Thakkinstian A.   +6 more
europepmc   +1 more source

Sentinel dosing: A proposed algorithm to guide decision making on which cohorts in early phase clinical pharmacology trials should use this approach

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim The aim of this paper is to describe a proposal for an algorithm to guide decision making on which cohorts in early phase pharmacology trials should employ a sentinel approach, thereby standardising and harmonising practices, and improving decision making around sentinel dosing.
Jules A. A. C. Heuberger, Perry de Jongh, Ewoud‐Jan van Hoogdalem, Wim Tamminga, Pieter de Graeff, Geert Jan Groeneveld   +5 more
wiley   +1 more source